News

Theratechnologies claimed that Egrifta, the first FDA-approved treatment for lipodystrophy, is a growth hormone releasing factor (GRF)drug that is administered in a once-daily injection. Egrifta was evaluated in

Adolor said that the compound was previously studied by a pharmaceutical company in late-stage clinical trials in over 1,000 patients for the treatment of depression, where it demonstrated

SurModics has posted a net loss of $21.66m for the fourth quarter 2010, or $1.25 loss per diluted share, compared to net income of $2.71m, or $0.16 per

The Bloom-DM study evaluated obese and overweight patients with type 2 diabetes who were randomised to Lorcaserin 10mg BID, Lorcaserin 10mg dosed once daily (QD) or placebo. The

LaRosa will report to Steve Andrzejewski, CEO of Nycomed US. He will be the chief legal advisor of the company and oversee all of the company’s legal and

GSK has not been charged with a crime and was not identified in the indictment. The indictment states that in October 2002, the FDA asked for information about

Huifeng develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production As per the terms of agreement, Jucheng shall provide $3.9m

The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic and autoimmune diseases. Antigen Express said that the proprietary vaccine being

The results from this trial are expected in the second quarter of 2011 and will be used in evaluating potential further clinical development of Bafetinib in patients with